OnKure

OnKure Therapeutics is a publicly listed company based in the US. OnKure is focused on the development of PI3Ka mutant subtype inhibitors. PI3Ka is a key oncogenic driver in a variety of cancers. The company’s lead product, OKI-219, is in a Phase I clinical study in breast cancer. Abingworth portfolio company Reneo Therapeutics merged with OnKure in 2024 and the company is listed on Nasdaq with the ticker: OKUR